Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

<h4>Background</h4>In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine.<h4>Objective</h4>To identify individuals with initial viral suppression (plasma HIV-1 RN...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan Z Li, Chanson J Brumme, Michael M Lederman, Zabrina L Brumme, Hongying Wang, John Spritzler, Mary Carrington, Kathleen Medvik, Bruce D Walker, Robert T Schooley, Daniel R Kuritzkes, AIDS Clinical Trials Group A5197 Study Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0034134&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items